{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:06Z","timestamp":1787010126673,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purposes of review<\/jats:title>\n                    <jats:p>\n                      The inflammatory response in sepsis raises circulatory levels of gaseous transmitters (gasotransmitters) nitric oxide (NO) and hydrogen sulfide (H\n                      <jats:sub>2<\/jats:sub>\n                      S), both of which generate and sustain septic shock. Current best practices, including early intravenous fluid, early antibiotics, and vasopressor support, do not target gasotransmitters. A single 5-g dose of intravenous hydroxocobalamin (high-dose HOC) is a safe intervention that targets circulating gasotransmitters. In this review, we provide an overview of the role of gasotransmitters in septic shock, outline the rationale for high-dose HOC in septic shock, and summarize clinical evidence for high-dose HOC in septic shock.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      NO and H\n                      <jats:sub>2<\/jats:sub>\n                      S are elevated early in septic shock, activate inflammatory pathways, and higher levels correlate with greater severity of illness. Preclinical evidence demonstrates high-dose HOC improves outcomes in models of septic shock by scavenging circulating NO and H\n                      <jats:sub>2<\/jats:sub>\n                      S. Multiple case series and a Phase IIa trial show that high-dose HOC is a safe intervention that reduces vasopressor dose in adults with septic shock. Without high-level evidence, clinicians across the United States are using high-dose HOC for adults with septic shock.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>High-dose HOC is a promising, nontoxic intervention that targets the pathophysiologic pathway of septic shock. Despite compelling observational and Phase IIa trial data, a pivotal phase III trial testing high-dose HOC in adults with septic shock is required before widespread use can be recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001289","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:02:17Z","timestamp":1750068137000},"page":"387-392","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Biologic rationale and evidence for high-dose hydroxocobalamin in septic shock"],"prefix":"10.1097","volume":"31","author":[{"given":"Jayshil J.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Willoughby","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"R1-20250819","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMra2403213","article-title":"Sepsis and septic shock","volume":"391","author":"Meyer","year":"2024","journal-title":"N Engl J Med"},{"key":"R2-20250819","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","article-title":"Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group","volume":"273","author":"Abraham","year":"1995","journal-title":"JAMA"},{"key":"R3-20250819","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"R4-20250819","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group","volume":"25","author":"Opal","year":"1997","journal-title":"Crit Care Med"},{"key":"R5-20250819","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","article-title":"Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock","volume":"32","author":"Lopez","year":"2004","journal-title":"Crit Care Med"},{"key":"R6-20250819","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cvr\/28.1.34","article-title":"Effects of a nitric oxide synthase inhibitor in humans with septic shock","volume":"28","author":"Petros","year":"1994","journal-title":"Cardiovasc Res"},{"key":"R7-20250819","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1097\/CCM.0000000000005320","article-title":"IV vitamin C in critically ill patients: a systematic review and meta-analysis","volume":"50","author":"Patel","year":"2022","journal-title":"Crit Care Med"},{"key":"R8-20250819","first-page":"1","article-title":"Gases in sepsis: novel mediators and therapeutic targets","volume":"23","author":"Zhu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R9-20250819","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1164\/ajrccm.161.6.9812004","article-title":"Effects of nitric oxide in septic shock","volume":"161","author":"Vincent","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R10-20250819","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1111\/bph.13815","article-title":"Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system","volume":"174","author":"Cirino","year":"2017","journal-title":"Br J Pharmacol"},{"key":"R11-20250819","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.1209855","article-title":"H2S: a universal defense against antibiotics in bacteria","volume":"334","author":"Shatalin","year":"2011","journal-title":"Science"},{"key":"R12-20250819","first-page":"208","article-title":"Potential role of hydrogen sulfide in the pathogenesis of vascular dysfunction in septic shock","volume":"11","author":"Coletta","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"R13-20250819","doi-asserted-by":"crossref","first-page":"e0121621","DOI":"10.1371\/journal.pone.0121621","article-title":"Interactions of the gasotransmitters contribute to microvascular tone (dys)regulation in the preterm neonate","volume":"10","author":"Dyson","year":"2015","journal-title":"PLoS One"},{"key":"R14-20250819","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0163-4453(03)00043-4","article-title":"Changes in arterial hydrogen sulfide (H(2)S) content during septic shock and endotoxin shock in rats","volume":"47","author":"Hui","year":"2003","journal-title":"J Infect"},{"key":"R15-20250819","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1096\/fj.04-3583fje","article-title":"Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J"},{"key":"R16-20250819","doi-asserted-by":"crossref","first-page":"L1193","DOI":"10.1152\/ajplung.00489.2005","article-title":"Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse","volume":"290","author":"Zhang","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R17-20250819","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/SHK.0b013e31822bcfd0","article-title":"Total plasma sulfide as a marker of shock severity in nonsurgical adult patients","volume":"36","author":"Goslar","year":"2011","journal-title":"Shock"},{"key":"R18-20250819","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.181.6.4320","article-title":"Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis","volume":"181","author":"Zhang","year":"2008","journal-title":"J Immunol"},{"key":"R19-20250819","doi-asserted-by":"crossref","first-page":"L960","DOI":"10.1152\/ajplung.00388.2006","article-title":"Hydrogen sulfide acts as an inflammatory mediator in cecal ligation and puncture-induced sepsis in mice by upregulating the production of cytokines and chemokines via NF-kappaB","volume":"292","author":"Zhang","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R20-20250819","doi-asserted-by":"crossref","first-page":"e24535","DOI":"10.1371\/journal.pone.0024535","article-title":"Hydrogen sulfide and neurogenic inflammation in polymicrobial sepsis: involvement of substance P and ERK-NF-kappaB signaling","volume":"6","author":"Ang","year":"2011","journal-title":"PLoS One"},{"issue":"(Suppl 1)","key":"R21-20250819","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15563650600811755","article-title":"Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study","volume":"44","author":"Uhl","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"R22-20250819","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/15563650701829763","article-title":"Changes in blood pressure after administration of hydroxocobalamin: relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers","volume":"46","author":"Uhl","year":"2008","journal-title":"Clin Toxicol (Phila)"},{"key":"R23-20250819","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0022-3565(25)09522-9","article-title":"Hydroxocobalamin (vitamin B12a) prevents and reverses endotoxin-induced hypotension and mortality in rodents: role of nitric oxide","volume":"273","author":"Greenberg","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-20250819","doi-asserted-by":"crossref","first-page":"741804","DOI":"10.1155\/2013\/741804","article-title":"Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression","volume":"2013","author":"Sampaio","year":"2013","journal-title":"Mediators Inflamm"},{"key":"R25-20250819","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/1440-1681.13060","article-title":"A prospective, randomized trial of intravenous hydroxocobalamin versus norepinephrine or saline for treatment of lipopolysaccharide-induced hypotension in a swine model","volume":"46","author":"Bebarta","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"(1\u20133)","key":"R26-20250819","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tox.2007.09.009","article-title":"Prevention of hydrogen sulfide (H2S)-induced mouse lethality and cytotoxicity by hydroxocobalamin (vitamin B(12a))","volume":"242","author":"Truong","year":"2007","journal-title":"Toxicology"},{"key":"R27-20250819","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/15563650.2014.990976","article-title":"High-dose hydroxocobalamin administered after H2S exposure counteracts sulfide-poisoning-induced cardiac depression in sheep","volume":"53","author":"Haouzi","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"R28-20250819","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ncp.10327","article-title":"High-dose vitamin B12 in vasodilatory shock: a narrative review","volume":"34","author":"Patel","year":"2019","journal-title":"Nutr Clin Pract"},{"key":"R29-20250819","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1053\/j.jvca.2023.04.006","article-title":"Hydroxocobalamin for vasodilatory hypotension in shock: a systematic review with meta-analysis for comparison to methylene blue","volume":"37","author":"Brokmeier","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R30-20250819","first-page":"e0408","article-title":"Hydroxocobalamin in refractory septic shock: a retrospective case series","volume":"3","author":"Sacco","year":"2021","journal-title":"Crit Care Explor"},{"key":"R31-20250819","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1213\/XAA.0000000000000928","article-title":"Use of high-dose hydroxocobalamin for septic shock: a case report","volume":"12","author":"Lin","year":"2019","journal-title":"A&A Pract"},{"key":"R32-20250819","first-page":"e13388","article-title":"Extended duration infusion of hydroxocobalamin for vasoplegic rescue in septic shock","volume":"13","author":"Gerdes","year":"2021","journal-title":"Cureus"},{"key":"R33-20250819","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.chest.2022.09.021","article-title":"High-dose IV hydroxocobalamin (vitamin B12) in septic shock: a double-blind, allocation-concealed, placebo-controlled single-center pilot randomized controlled trial (the intravenous hydroxocobalamin in septic shock trial)","volume":"163","author":"Patel","year":"2023","journal-title":"Chest"},{"key":"R34-20250819","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcrc.2021.09.024","article-title":"Effects of a single bolus of hydroxocobalamin on hemodynamics in vasodilatory shock","volume":"67","author":"Ritter","year":"2022","journal-title":"J Crit Care"},{"key":"R35-20250819","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00003246-199303000-00027","article-title":"Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity","volume":"21","author":"Zerbe","year":"1993","journal-title":"Crit Care Med"},{"key":"R36-20250819","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/15563659309000395","article-title":"Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers","volume":"31","author":"Forsyth","year":"1993","journal-title":"J Toxicol Clin Toxicol"},{"issue":"(Suppl 1)","key":"R37-20250819","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/15563650600811870","article-title":"Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8\u200ayears of experience in the Paris Fire Brigade","volume":"44","author":"Fortin","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"R38-20250819","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.annemergmed.2007.01.026","article-title":"Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation","volume":"49","author":"Borron","year":"2007","journal-title":"Ann Emerg Med"},{"key":"R39-20250819","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ckj\/sfx004","article-title":"High-dose hydroxocobalamin for vasoplegic syndrome causing false blood leak alarm","volume":"10","author":"Cheungpasitporn","year":"2017","journal-title":"Clin Kidney J"},{"key":"R41-20250819","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"R42-20250819","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2025.01.016","article-title":"Use of high-dose hydroxocobalamin for septic shock","author":"Carr","year":"2025","journal-title":"Chest"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:01:48Z","timestamp":1755626508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001289","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}